Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Non-Current Assets: 2011-2024

Historic Non-Current Assets for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $157.3 million.

  • Adma Biologics' Non-Current Assets rose 129.25% to $166.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.0 million, marking a year-over-year increase of 129.25%. This contributed to the annual value of $157.3 million for FY2024, which is 117.92% up from last year.
  • According to the latest figures from FY2024, Adma Biologics' Non-Current Assets is $157.3 million, which was up 117.92% from $72.2 million recorded in FY2023.
  • Adma Biologics' Non-Current Assets' 5-year high stood at $157.3 million during FY2024, with a 5-year trough of $53.9 million in FY2020.
  • Moreover, its 3-year median value for Non-Current Assets was $78.1 million (2022), whereas its average is $102.5 million.
  • Per our database at Business Quant, Adma Biologics' Non-Current Assets declined by 7.55% in 2023 and then skyrocketed by 117.92% in 2024.
  • Over the past 5 years, Adma Biologics' Non-Current Assets (Yearly) stood at $53.9 million in 2020, then rose by 25.20% to $67.5 million in 2021, then increased by 15.60% to $78.1 million in 2022, then dropped by 7.55% to $72.2 million in 2023, then surged by 117.92% to $157.3 million in 2024.